Gluconorm G2 D Tablet SR is a combination oral antidiabetic medication formulated to improve glycemic control in patients with type 2 diabetes mellitus. Each sustained-release tablet contains Glimepiride 2 mg, Metformin 500 mg, and Vitamin D3 400 IU. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to enhanced glucose uptake and utilization. The sustained-release formulation ensures a gradual release of active ingredients, promoting better tolerability and adherence through reduced gastrointestinal side effects commonly associated with metformin. The inclusion of Vitamin D3 supports bone health and may have a beneficial role in modulating insulin secretion and sensitivity. Gluconorm G2 D is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes inadequately controlled on monotherapy. It is essential to monitor renal function prior to and during therapy due to metformin’s renal clearance. Contraindications include severe renal impairment, metabolic acidosis, and known hypersensitivity to any component. Regular monitoring of blood glucose and periodic assessment of vitamin D levels are recommended to optimize therapeutic outcomes and minimize adverse effects.